Evidence map›Paper›PMID 41607601›Full record

ArticleMediterranean journal of rheumatology2025

HCV Reactivation Risk in Patients Undergoing Treatment for Inflammatory Arthritis and Connective Tissue Diseases.

Maria Pappa, Theodoros Androutsakos, Anastasios Karamanakos, Evangelia Mole, Souzana Gazi, Fabiola Atzeni, Marco Sebastiani, Konstantinos D Vassilakis, Charalampos Papagoras, Nikolaos Kougkas and 1 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Mediterranean journal of rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maria PappaFirst Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Theodoros AndroutsakosDepartment of Pathophysiology, National and Kapodistrian University of Athens, Athens, Greece.
Anastasios KaramanakosDepartment of Rheumatology, "Evangelismos" Hospital, Athens, Greece.
Evangelia MoleDepartment of Rheumatology, "KAT" Hospital, Athens, Greece.
Souzana GaziDepartment of Rheumatology, "KAT" Hospital, Athens, Greece.
Fabiola AtzeniRheumatology Unit, Department of Internal and Experimental Medicine, University of Messina, Messina, Italy.
Marco SebastianiRheumatology Unit, AUSL Piacenza, Italy.
Konstantinos D VassilakisFirst Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Charalampos PapagorasFirst Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.
Nikolaos KougkasDepartment of Rheumatology, 4th Department of Internal Medicine, Aristotle University, Hippokration Hospital, Thessaloniki, Greece.
George E FragoulisFirst Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

DMARDsHepatitis Cimmunosuppressivesinflammatory arthritisreactivation riskrheumatic diseases

Identifiers

PMID41607601
PMCPMC12835930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.